genetic familial mutations
494 articles
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
A Registry for Those at Risk for Pancreatic Cancer
Dr. Robert Kurtz founded the Pancreatic Tumor Registry at Memorial Sloan Kettering to learn more about the genetic mutations that cause pancreatic cancer.
Understanding a Family’s Risk for Pancreatic Cancer
A tumor registry studies the genetics of pancreatic cancer to determine risk factors for families.
A Liquid Biopsy for Pancreatic Cancer
Dr. Bert Vogelstein and his team at Johns Hopkins are working with a blood test called a liquid biopsy, which tests cells for mutations related to cancer.
Pancreatic Cancer Tissue Helps Unlock the Disease’s Secrets
Dr. Christine Iacobuzio-Donahue at Memorial Sloan Kettering is using techniques from evolutionary biology to learn how pancreatic cancer grows.
Understanding Who Is at High Risk for Pancreatic Cancer
Who is high-risk for pancreatic cancer? Oncologist Dr. Matthew Yurgelun explains high-risk populations and what steps to take if you meet the criteria.
Frequently Asked Questions About Pancreatic Cancer
Have you or someone you love just been diagnosed with pancreatic cancer? Learn some basic facts about this disease from our FAQ.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Early Detection Trial for People at Higher Risk of Pancreatic Cancer
Relatives of pancreatic cancer patients or people who carry certain mutations can participate in an early detection clinical trial.
New Study Targets Specific BRAF Mutation
One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian.
Crafting a Medical Family Tree
Dr. Diane Simeone and genetic counselor Jessica Everett explain why it is important to create a medical family tree for pancreatic cancer.
BRCA Mutations and Pancreatic Cancer
Let’s Win, the National Alliance for Hispanic Health, and the Basser Center for BRCA teamed up to present a webinar on BRCA mutations and pancreatic cancer.